ImmuCell Corporation (ICCC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $97.73M
Last updated: Nov 17, 2026 at 11:06 AM ET
ImmuCell Corporation (ICCC) Financials: Revenue, Profit and Cash Flow
ImmuCell reported revenue of $27.64M for the fiscal year ended Dec 31, 2025, up 4.3% from the year before. That year, net income was -$1.04M with a net margin of -3.8%, operating cash flow was $2.48M and free cash flow was $1.22M. The quarter ended Sep 30, 2026 had revenue of $8.04M and net income of $952.51K.
Revenue and Margins
The operating margin was 6.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $9.54M, a compound annual rate of 12.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $27.64M | +4.3% | 41.4% | 6.0% | -3.8% |
| Dec 2024 | $26.49M | +51.6% | 30.0% | -6.2% | -8.1% |
| Dec 2023 | $17.47M | -5.9% | 22.1% | -32.9% | -33.1% |
| Dec 2022 | $18.57M | -3.5% | 41.2% | -12.4% | -13.4% |
| Dec 2021 | $19.24M | +25.4% | 45.0% | 1.3% | -0.4% |
| Dec 2020 | $15.34M | +11.8% | 44.7% | -9.0% | -6.7% |
| Dec 2019 | $13.72M | +24.9% | 49.1% | -7.0% | -9.4% |
| Dec 2018 | $10.99M | +5.3% | 47.3% | -13.2% | -21.1% |
| Dec 2017 | $10.43M | +9.3% | 50.1% | -2.3% | -1.6% |
| Dec 2016 | $9.54M | N/A | 56.8% | 9.3% | 5.3% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.64M | $26.49M | $17.47M | $18.57M | $19.24M | $15.34M | $13.72M | $10.99M | $10.43M | $9.54M |
| Cost of revenue | $16.20M | $18.55M | $13.60M | $10.92M | $10.59M | $8.48M | $6.98M | $5.79M | $5.21M | $4.12M |
| Gross profit | $11.45M | $7.94M | $3.87M | $7.65M | $8.66M | $6.86M | $6.74M | $5.19M | $5.22M | $5.42M |
| Research and development | $3.04M | $3.90M | $4.39M | $4.49M | $4.17M | $4.35M | $3.69M | $3.52M | $2.05M | $1.24M |
| Operating income | $1.65M | -$1.64M | -$5.75M | -$2.30M | $257.38K | -$1.38M | -$953.91K | -$1.45M | -$242.84K | $890.20K |
| Net income | -$1.04M | -$2.16M | -$5.77M | -$2.49M | -$78.29K | -$1.02M | -$1.30M | -$2.32M | -$168.15K | $508.45K |
| EBITDA | $1.76M | $583.27K | -$3.03M | $9.11K | $2.39M | $1.32M | $1.00M | -$339.34K | $465.95K | $1.56M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.04M | $7.19M | $10.36M | $7.63M | $5.51M | $6.44M | $8.07M | $7.75M | $6.01M | $5.47M | $7.26M | $5.10M |
| Gross profit | $3.56M | $2.44M | $4.66M | $2.91M | $2.36M | $2.82M | $3.35M | $2.83M | $1.58M | $1.23M | $2.30M | $1.26M |
| Operating income | $957.77K | $1.93M | $1.97M | -$57.96K | $20.07K | $569.56K | $1.12M | $621.39K | -$574.89K | -$1.39M | -$300.05K | -$1.00M |
| Net income | $952.51K | $1.83M | $1.94M | -$2.85M | -$139.75K | $501.88K | $1.45M | $514.55K | -$701.69K | -$1.53M | -$437.87K | -$1.14M |
Balance Sheet
As of Dec 2025, total debt of $9.10M exceeded cash and equivalents by $5.29M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $42.53M | $45.10M | $43.81M | $44.86M | $44.47M | $40.35M | $38.69M | $32.73M | $34.30M | $24.70M |
| Current assets | $16.94M | $15.04M | $11.47M | $14.07M | $16.26M | $12.16M | $13.19M | $6.42M | $7.51M | $14.35M |
| Cash and equivalents | $3.81M | $3.76M | $978.74K | $5.79M | $10.19M | $6.95M | $6.29M | $2.52M | $3.80M | $5.15M |
| Total liabilities | $15.48M | $17.58M | $18.82M | $14.48M | $11.89M | $12.08M | $9.70M | $10.99M | $10.70M | $4.98M |
| Short-term debt | $1.61M | $1.50M | $1.43M | $1.04M | $812.21K | $760.34K | $1.27M | $1.34M | $316.63K | $133.27K |
| Long-term debt | $7.49M | $9.04M | $10.54M | $9.19M | $8.33M | $8.74M | $7.15M | $8.42M | $8.64M | $2.88M |
| Shareholder equity | $27.06M | $27.52M | $24.99M | $30.38M | $32.58M | $28.27M | $28.99M | $21.74M | $23.59M | $19.72M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $47.96M | $46.63M | $44.11M | $42.53M | $45.73M | $46.72M | $45.62M | $45.10M | $44.45M | $41.86M | $43.05M | $43.81M |
| Total liabilities | $15.18M | $15.26M | $14.97M | $15.48M | $15.93M | $16.85M | $16.63M | $17.58M | $18.04M | $18.40M | $18.41M | N/A |
| Cash and equivalents | $7.91M | $8.86M | $6.81M | $3.81M | $3.89M | $6.00M | $4.60M | $3.76M | $3.81M | $1.32M | $960.35K | $979.00K |
| Shareholder equity | $32.77M | $31.37M | $29.14M | $27.06M | $29.80M | $29.87M | $28.99M | $27.52M | $26.41M | $23.46M | $24.64M | N/A |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 49.2% of operating cash flow. Share repurchases came to 5.6% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.48M | $357.90K | -$4.67M | -$1.54M | $954.17K | $1.32M | $233.51K | -$373.40K | $1.18M | -$222.31K |
| Capital expenditures | $1.25M | $465.73K | $1.89M | $3.98M | $2.61M | $4.07M | $1.39M | $2.03M | $17.76M | $4.05M |
| Free cash flow | $1.22M | -$107.82K | -$6.57M | -$5.52M | -$1.65M | -$2.76M | -$1.16M | -$2.40M | -$16.58M | -$4.27M |
| Share repurchases | $67.88K | $291.83K | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$1.21M | -$461.23K | -$1.89M | -$3.96M | -$1.60M | -$2.57M | -$3.40M | -$1.79M | -$12.27M | -$4.52M |
| Financing cash flow | -$1.21M | $2.88M | $1.75M | $1.11M | $3.88M | $1.91M | $6.94M | $889.62K | $9.75M | $8.32M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $755.91K | $3.02M | $3.57M | $482.54K | -$1.18M | $1.60M | $1.57M | -$3.05K | -$639.33K | $581.78K | $418.50K | -$723.07K |
| Capital expenditures | $1.35M | $733.94K | $177.23K | $172.31K | $593.92K | $155.16K | $329.05K | $196.22K | $88.41K | $110.74K | $70.36K | $33.78K |
| Free cash flow | -$589.36K | $2.29M | $3.40M | $310.24K | -$1.78M | $1.45M | $1.24M | -$199.27K | -$727.74K | $471.04K | $348.15K | -$756.85K |
Frequently Asked Questions About ICCC
What is ImmuCell's annual revenue?
ImmuCell reported revenue of $27.64M for the fiscal year ended Dec 31, 2025.
How fast is ImmuCell's revenue growing?
Revenue was up 4.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 14.2%.
Is ImmuCell profitable?
No. ImmuCell reported net income of -$1.04M for the fiscal year ended Dec 31, 2025, with a net margin of -3.8%.
How much free cash flow does ICCC generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $2.48M minus capital expenditures of $1.25M produced free cash flow of $1.22M.
How much debt does ImmuCell have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $7.49M, short-term debt of $1.61M and cash and equivalents of $3.81M.
ICCC pages: Overview, Earnings, Financials, Valuation, Competitors